Shenzhen Neptunus Interlong Bio-technique Company Limited

SEHK:8329 Stock Report

Market Cap: HK$261.8m

Shenzhen Neptunus Interlong Bio-technique Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shenzhen Neptunus Interlong Bio-technique.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth11.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Nov 07
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

Sep 05
Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Apr 19
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Oct 03
These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Mar 29
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

Sep 28
We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Aug 18
A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Jun 06
Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Dec 15
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Dec 29
Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Nov 24
Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shenzhen Neptunus Interlong Bio-technique has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:8329 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20241,05432108127N/A
3/31/20241,04527N/AN/AN/A
12/31/20231,065243854N/A
9/30/20231,12064N/AN/AN/A
6/30/20231,10364-77-56N/A
3/31/20231,07160N/AN/AN/A
12/31/2022987544261N/A
9/30/202293147N/AN/AN/A
6/30/2022886374660N/A
3/31/202283531N/AN/AN/A
12/31/202183936-85-70N/A
9/30/202186833N/AN/AN/A
6/30/202196338-72-42N/A
3/31/20211,05643N/AN/AN/A
12/31/20201,031375694N/A
9/30/20201,07752N/AN/AN/A
6/30/20201,06559118156N/A
3/31/20201,05957N/AN/AN/A
12/31/20191,081602760N/A
9/30/20191,00656N/AN/AN/A
6/30/201993752-524N/A
3/31/201987947N/AN/AN/A
12/31/201886748-325N/A
9/30/201886243N/AN/AN/A
6/30/201884843-626N/A
3/31/201883551N/AN/AN/A
12/31/201779050N/A56N/A
9/30/201780364N/AN/AN/A
6/30/201777264N/A77N/A
3/31/201777765N/AN/AN/A
12/31/201675963N/A83N/A
9/30/201673837N/AN/AN/A
6/30/201672629N/A43N/A
3/31/201671320N/AN/AN/A
12/31/201572121N/A62N/A
9/30/201566419N/AN/AN/A
6/30/201566223N/A60N/A
3/31/201565031N/AN/AN/A
12/31/201464833N/A39N/A
9/30/201463330N/AN/AN/A
6/30/201463027N/A60N/A
3/31/201460337N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8329's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 8329's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 8329's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8329's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 8329's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8329's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 04:18
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Neptunus Interlong Bio-technique Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution